Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.

In vivo (Athens, Greece) - 1 Jan 2000

Lee Juhun, Kim Jong Mi, Lee Yoon Hee, Chong Gun Oh, Lee Nan Young, Lee In Hee, Park Ji Young, Hong Dae Gy

Abstract excerpt

BACKGROUND/AIM: Mutations of BRCA1/2 improve cancer prognosis due to their better response to platinum-based chemotherapy. This study evaluated overall survival (OS) and progression-free survival (PFS) under similar conditions of first-line adjuvant chemotherapy within seven years in high-grade serous ovarian cancer (HGSOC). PATIENTS AND METHODS: A total of 160 patients were enrolled. The pathogenic BRCA1/2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Cystadenocarcinoma, Serous

Share to Mutation

Share to Neoplasm Staging

Share to Ovarian Neoplasms

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 35738605
DOI: 10.21873/invivo.12910
PMCID: PMC9301411

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.PMID 35738605Read ↗

Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancerSemantic proximity Read ↗

The Impact of Pathogenic BRCA1/2 Tumor Mutation Status on Advanced Stage-High Grade Serous Epithelial Ovarian Cancer Survival OutcomeSemantic proximity Read ↗

BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized TherapeuticsSemantic proximity Read ↗

Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.Semantic proximity Read ↗

A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.Semantic proximity Read ↗

BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancerSemantic proximity Read ↗

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.Semantic proximity Read ↗

Somatic Mutations in BRCA2 BRC Repeat Associated with Outcome in Patients with High Grade Serous Ovarian CancerSemantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.